{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:40:07Z","timestamp":1792694407526,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-breast-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clbc.2024.07.006","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T01:09:39Z","timestamp":1721869779000},"page":"e56-e62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of the Effect of Menopausal Status and BMI on Polymorphisms in Fas\/Fas L and the Risk of Breast Cancer"],"prefix":"10.1016","volume":"25","author":[{"given":"Zahra","family":"Tahmasebi Fard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2024.07.006_bib0001","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41419-020-2654-2","article-title":"BIK drives an aggressive breast cancer phenotype through sublethal apoptosis and predicts poor prognosis of ER-positive breast cancer","volume":"11","author":"Pandya","year":"2020","journal-title":"Cell Death Dis"},{"issue":"49","key":"10.1016\/j.clbc.2024.07.006_bib0002","doi-asserted-by":"crossref","first-page":"e18240","DOI":"10.1097\/MD.0000000000018240","article-title":"Correlation between FAS single nucleotide polymorphisms and breast carcinoma susceptibility in Asia","volume":"98","author":"Ying","year":"2019","journal-title":"Medicine"},{"issue":"16","key":"10.1016\/j.clbc.2024.07.006_bib0003","first-page":"P11522","article-title":"Blockade of fas signaling in breast cancer cells suppresses tumor growth and metastasis via disruption of fas signaling-initiated cancer-related inflammation","volume":"289","author":"Qiuyan","year":"2014","journal-title":"Signal Transduct Immunol"},{"key":"10.1016\/j.clbc.2024.07.006_bib0004","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-3-030-30845-2_11","article-title":"The CD95\/CD95L signaling pathway: a role in carcinogenesis","volume":"3","author":"Fouqu\u00e9","year":"2020","journal-title":"Cancer Immunol"},{"key":"10.1016\/j.clbc.2024.07.006_bib0005","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/s41598-020-58211-3","article-title":"The mechanism of how CD95\/Fas activates the Type I IFN\/STAT1 axis, driving cancer stemness in breast cancer","volume":"10","author":"Qadir","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.clbc.2024.07.006_bib0006","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nature09075","article-title":"CD95 promotes tumour growth","volume":"465","author":"Chen","year":"2010","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.clbc.2024.07.006_bib0007","first-page":"120","article-title":"Prognostic value of the Fas\/Fas ligand system in breast cancer","volume":"17","author":"B\u0119benek","year":"2013","journal-title":"Contemp Oncol (Pozn)"},{"key":"10.1016\/j.clbc.2024.07.006_bib0008","doi-asserted-by":"crossref","first-page":"15610","DOI":"10.18632\/oncotarget.14779","article-title":"Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer","volume":"8","author":"Blok","year":"2017","journal-title":"Oncotarget"},{"issue":"49","key":"10.1016\/j.clbc.2024.07.006_bib0009","doi-asserted-by":"crossref","first-page":"e18240","DOI":"10.1097\/MD.0000000000018240","article-title":"Correlation between FAS single nucleotide polymorphisms and breast carcinoma susceptibility in Asia","volume":"98","author":"Ying Ch","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.clbc.2024.07.006_bib0010","first-page":"23","article-title":"Status of FAS and FAS ligand gene polymorphisms in patients with breast cancer in Northeastern IRAN","volume":"7","author":"Jalali","year":"2018","journal-title":"Rep Biochem Mol Biol"},{"issue":"13","key":"10.1016\/j.clbc.2024.07.006_bib0011","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1111\/1471-0528.15412","article-title":"FAS A-670G and Fas Ligand IVS2nt A 124G polymorphisms are significantly increased in women with preeclampsia and may contribute to HELLP syndrome: a case-controlled study","volume":"125","author":"Raguemaa","year":"2018","journal-title":"BJOG"},{"issue":"2","key":"10.1016\/j.clbc.2024.07.006_bib0012","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3390\/cancers15020485","article-title":"Obesity and cancer: a current overview of epidemiology, pathogenesis, outcomes, and management","volume":"15","author":"Pati","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2024.07.006_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpobgyn.2023.102348","article-title":"Obesity and menopause","volume":"88","author":"Opoku","year":"2023","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"2","key":"10.1016\/j.clbc.2024.07.006_bib0014","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.gendis.2019.09.006","article-title":"Obesity as potential breast cancer risk factor for postmenopausal women","volume":"8","author":"Mohanty","year":"2021","journal-title":"Genes & Diseases"},{"issue":"7","key":"10.1016\/j.clbc.2024.07.006_bib0015","first-page":"1","article-title":"Fas\u2013fas ligand: checkpoint of T cell functions in multiple sclerosis","volume":"27","author":"-Volpe","year":"2016","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.clbc.2024.07.006_bib0016","doi-asserted-by":"crossref","first-page":"831","DOI":"10.31557\/APJCP.2020.21.3.831","article-title":"Fas ligand (FasL) in association with tumor-infiltrating lymphocytes (TILs) in early stage cervical cancer","volume":"21","author":"Dewi Anggraeni","year":"2020","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"10.1016\/j.clbc.2024.07.006_bib0017","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.celrep.2014.02.035","article-title":"Death induced by CD95 or CD95 ligand elimination","volume":"7","author":"Hadji","year":"2014","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.clbc.2024.07.006_bib0019","first-page":"822","article-title":"FasL:fas ratio\u2013a prognostic factor in breast carcinomas","volume":"60","author":"Reimer","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2024.07.006_bib0020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00432-017-2551-y","article-title":"Induction of apoptosis in breast cancer cells in vitro by Fas ligand reverse signaling","volume":"144","author":"Kolben","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2024.07.006_bib0021","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/09674845.2020.1747182","article-title":"Polymorphisms rs763110 in FASL is linked to hepatitis C virus infection among high-risk populations","volume":"77","author":"Huang","year":"2020","journal-title":"Br J Biomed Sci"},{"issue":"9","key":"10.1016\/j.clbc.2024.07.006_bib0022","doi-asserted-by":"crossref","first-page":"e74543","DOI":"10.1371\/journal.pone.0074543","article-title":"FASL rs763110 polymorphism contributes to cancer risk: an updated meta-analysis involving 43,295 subjects . Meta-Analysis","volume":"8","author":"Xu","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.clbc.2024.07.006_bib0023","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00066-013-0485-0","article-title":"Association of genetic variants in apoptosis genes FAS and FASL with radiation-induced late toxicity after prostate cancer radiotherapy","volume":"190","author":"Thurner","year":"2014","journal-title":"Strahlenther Onkol"},{"issue":"13","key":"10.1016\/j.clbc.2024.07.006_bib0024","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/1471-0528.15412","article-title":"FAS A-670G and Fas Ligand IVS2nt A 124G polymorphisms are significantly increased in women with preeclampsia and may contribute to HELLP syndrome: a case-controlled study","volume":"125","author":"Raguemaa","year":"2018","journal-title":"BJOG"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924002039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924002039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T02:00:34Z","timestamp":1736301634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820924002039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1526820924002039"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2024.07.006","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the Effect of Menopausal Status and BMI on Polymorphisms in Fas\/Fas L and the Risk of Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2024.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}